ADCT
ADC Therapeutics S.A.
NYSE · Healthcare · Biotechnology · CH
$1.35
+1.89%Year over year
Reported trailing growth
- Revenue
- +2.0%
- EBITDA
- +24.4%
- EBIT
- +29.5%
- EPS
- +57.8%
- Free cash flow
- +20.0%
- Operating cash flow
- +19.7%
Forward estimates
Based on analyst estimates
- Revenue
- +7.2%
- EBITDA
- +25.5%
- EPS
- -15.3%
Three-year CAGR
- Revenue
- -27.1%
- EBITDA
- +13.0%
- EBIT
- +17.0%
- Net income
- +9.6%
- EPS
- +30.9%
- Free cash flow
- -13.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026